BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35234619)

  • 1. Seroepidemiologic study on convalescent sera from dengue fever patients in Jinghong, Yunnan.
    Ma Y; Li M; Xie L; Gao N; Fan D; Feng K; Yao Y; Zhou Y; Sheng Z; Zhou H; Chen H; An J
    Virol Sin; 2022 Feb; 37(1):19-29. PubMed ID: 35234619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zika convalescent macaques display delayed induction of anamnestic cross-neutralizing antibody responses after dengue infection.
    Valiant WG; Huang YS; Vanlandingham DL; Higgs S; Lewis MG; Mattapallil JJ
    Emerg Microbes Infect; 2018 Jul; 7(1):130. PubMed ID: 30006514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.
    Shukla R; Ramasamy V; Shanmugam RK; Ahuja R; Khanna N
    Front Cell Infect Microbiol; 2020; 10():572681. PubMed ID: 33194810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model.
    Libraty DH; Acosta LP; Tallo V; Segubre-Mercado E; Bautista A; Potts JA; Jarman RG; Yoon IK; Gibbons RV; Brion JD; Capeding RZ
    PLoS Med; 2009 Oct; 6(10):e1000171. PubMed ID: 19859541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The human antibody response to dengue virus infection.
    Wahala WM; Silva AM
    Viruses; 2011 Dec; 3(12):2374-95. PubMed ID: 22355444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients.
    Chaichana P; Okabayashi T; Puiprom O; Sasayama M; Sasaki T; Yamashita A; Ramasoota P; Kurosu T; Ikuta K
    PLoS One; 2014; 9(3):e92173. PubMed ID: 24642752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.
    de Alwis R; Williams KL; Schmid MA; Lai CY; Patel B; Smith SA; Crowe JE; Wang WK; Harris E; de Silva AM
    PLoS Pathog; 2014 Oct; 10(10):e1004386. PubMed ID: 25275316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
    Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
    Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
    Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
    EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.
    Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W
    Front Immunol; 2018; 9():597. PubMed ID: 29740424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection.
    Wang Y; Si L; Luo Y; Guo X; Zhou J; Fang D; Yan H; Zeng G; Jiang L
    Appl Microbiol Biotechnol; 2015 Nov; 99(22):9685-98. PubMed ID: 26219500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults.
    Saito Y; Moi ML; Takeshita N; Lim CK; Shiba H; Hosono K; Saijo M; Kurane I; Takasaki T
    BMC Infect Dis; 2016 Oct; 16(1):578. PubMed ID: 27756212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibody response variation against dengue 3 strains.
    Alvarez M; Pavon-Oro A; Rodriguez-Roche R; Bernardo L; Morier L; Sanchez L; Alvarez AM; Guzmán MG
    J Med Virol; 2008 Oct; 80(10):1783-9. PubMed ID: 18712848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.
    Katzelnick LC; Montoya M; Gresh L; Balmaseda A; Harris E
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):728-33. PubMed ID: 26729879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of Dengue Virus Serotypes by Sera from Dengue-Infected Individuals Is Preferentially Directed to Heterologous Serotypes and Not against the Autologous Serotype Present in Acute Infection.
    Auerswald H; Kann S; Klepsch L; Hülsemann J; Rudnik I; Schreiber S; Buchy P; Schreiber M
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissecting the human serum antibody response to secondary dengue virus infections.
    Patel B; Longo P; Miley MJ; Montoya M; Harris E; de Silva AM
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005554. PubMed ID: 28505154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection.
    Moi ML; Takasaki T; Saijo M; Kurane I
    Trans R Soc Trop Med Hyg; 2013 Jan; 107(1):51-8. PubMed ID: 23296697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.